Royal Philips showcased enhancements to its cardiology portfolio at the Annual Scientific Session & Expo of the American College of Cardiology/World Congress of Cardiology event. Philips’ cardiology portfolio addresses ever-increasing demand for cost-effective diagnosis, treatment, monitoring and management of patients with heart conditions such as coronary artery disease, structural heart disease, arrhythmia and heart failure.
Highlighted introductions to the portfolio include the company’s latest compact portable ultrasound platform – Philips Ultrasound Compact System 5500 CV, its spectral-detector based CT scanner, Philips Spectral CT 7500, and Philips Intracardiac Echocardiography Catheter – VeriSight Pro 3D ICE.
Evidence-based cardiology innovation
In line with Philips’ commitment to supporting its innovations with clinical evidence, three of the company’s clinical partners presented the results of clinical studies at ACC.23/WCC that could help inform clinical guidelines
Dr. Eric Secemsky, Director of Vascular Intervention at Beth Israel Deaconess Medical Center (Boston, MA, USA) shared the results of a high-quality real-world evidence study of data for over a million U.S. Medicare patients to evaluate trends in the use of, and outcomes associated with, intravascular imaging (IVI) during percutaneous coronary intervention (PCI) procedures. Philips is a leader in IVI with its intravascular ultrasound (IVUS) solutions.
Dr. Mohamad Alkhouli, Professor of Medicine at Mayo Clinic School of Medicine (Rochester, MN, USA) presented a study on the real-world performance and safety of the Philips Intracardiac Echocardiography Catheter – VeriSight Pro 3D ICE
Dr. Sean Pokorney, Assistant Professor of Medicine and Member of the Duke Clinical Research Institute at Duke University School of Medicine (Durham, NC, USA) examined the hospitalization and healthcare expenditure benefits associated with guideline driven care and early extraction of infected cardiac implantable electronic devices (CIEDs), for which Philips is the market leader in lead management devices.
All three clinical studies were part of more than 110 ongoing clinical studies that support Philips image-guided therapy solutions with clinical evidence
Other highlighted innovations from its cardiology portfolio that Philips showcased at ACC.23/WCC are the company’s advanced image-guided therapy platform Philips Image-Guided Therapy System – Azurion; Philips Interventional Applications Platform – IntraSight interventional workspace; Philips IntelliSpace ECG providing fast, easy access to ECGs from almost anywhere in the medical facility; and Philips Mobile Cardiac Telemetry – MCOT ambulatory cardiac monitoring solution.
